Drug Developer City Therapeutics Files for US IPO
Why now
Thesis: Small biotech IPO tests healthcare risk appetite
Catalyst to watch: Pricing and first-day trading
Main risk: Weak demand postpones listing
Why it matters
New biotech IPO adds to healthcare issuance pipeline but single-firm filing has minimal market signal.
Related assets & topics
HealthcareSources
- googlenews · news.google.com · 2026-09-24 20:52 UTC
- googlenews · news.google.com · 2026-09-24 20:57 UTC
- googlenews · news.google.com · 2026-09-24 20:47 UTC